Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE ® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134063

Published: 2020

Journal Articles

A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma

Lawrence Liu, MD, Gao Feng, MD PhD MPH, Mark A. Fiala, MSW, Justin King, BS, Scott R. Goldsmith, MD, Tanya M. Wildes, MD MSCI, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS, Mark A. Schroeder, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-137023

Published: 2020

Journal Articles

A Preliminary Assessment of Heterozygous CFHR3-CFHR1 Deletion As a Permissive Mutation in Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome

Andrew Jay Portuguese, MD, Mark A Fiala, MSW, Tanya M. Wildes, MD MSCI, Ravi Vij, MBBS, Brea Lipe, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-134154

Published: 2020

Journal Articles

Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma

Cesar Rodriguez, MD, Anita D'Souza, MD MS, Nina Shah, MD, Peter M. Voorhees, MD, Ben Buelow, MD PhD, Ravi Vij, MBBS, Shaji K. Kumar, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-139893

Published: 2020

Journal Articles

Inhibition of HIF-1a By PX-478 Normalizes Blood Vessels, Improves Drug Delivery and Suppresses Progression and Dissemination in Multiple Myeloma

Barbara Muz, PhDMSc, Katherine Wasden, Kinan Alhallak, BSc, Amanda Jeske, BS, Feda Azab, Jennifer Sun, BSc, Justin King, BS, Daniel R. Kohnen, MBA, Ravi Vij, MBBS, Abdel Kareem Azab, PhD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-142154

Published: 2020

Journal Articles

Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Commpass Study

Lijun Yao, MS, Reyka G Jayasinghe, PhD, Beena E Thomas, Swati S Bhasin, PhD, Nicolas Fernandez, PhD, Taxiarchis Kourelis, MD, Deon Doxie, David E. Avigan, MD, Madhav V. Dhodapkar, MD, Shaji K. Kumar, MD, Ravi Vij, MBBS, Shaadi Mehr, PhD, Mark Hamilton, PhD, Hearn Jay Cho, MD PhD, Daniel Auclair, Sacha Gnjatic, PhD, Manoj Bhasin, PhD, Li Ding, PhD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-142534

Published: 2020

Journal Articles

A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma

Murali Janakiram, MD, Ravi Vij, MBBS, David S. Siegel, MD PhD, Ted Shih, PharmD, Sara Weymer, Bahram Valamehr, PhD, Yu-Waye Chu, MD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-137715

Published: 2020

Journal Articles

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Ravi Vij, MBBS, Thomas G. Martin, III, MD, Nitya Nathwani, MD, Mark A. Fiala, BS, Feng Gao, PhD, Abhinav Deol, MD, Francis K. Buadi, MB, CHB, Jonathan L. Kaufman, MD, Craig C Hofmeister, MDMPH, Tara K. Gregory, MD, Jesus G. Berdeja, MD, Ajai Chari, MD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 602.

https://doi.org/10.1182/blood-2019-130644

Published: 2019

Journal Articles

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study

Blood (2019) 134 (Supplement_1): 1872.

https://doi.org/10.1182/blood-2019-122908

Published: 2019

Journal Articles

TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma

Ben Buelow, MD PhD, Anita D'Souza, MBBS, Cesar Rodriguez, MD, Ravi Vij, MBBS, Rajneesh Nath, MD, Melinda Snyder, MS, Duy Pham, MBA, Ashwin Patel, PhD, Suhasini Iyer, PhD

Blood (2019) 134 (Supplement_1): 1874.

https://doi.org/10.1182/blood-2019-123220

Published: 2019

Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

David Cella, PhD, Jan McKendrick, Harrison Davis, Ravi Vij, MBBS, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 2190.

https://doi.org/10.1182/blood-2019-122668

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages

Tianjiao Wang, BA, Hua Sun, PhD, Daniel Cui Zhou, BA, Ruiyang Liu, BS, Lijun Yao, MS, Mark A. Fiala, MSW, Daniel R. Kohnen, MBA, Julie O'Neal, PhD, Michael P. Rettig, PhD, Jared S Fowles, PhD, Stephen T. Oh, MD, Reyka G Jayasinghe, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD, Li Ding, PhD

Blood (2019) 134 (Supplement_1): 364.

https://doi.org/10.1182/blood-2019-131361

Published: 2019

Journal Articles

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Linda Kachuri, PhD MPH, Zhaohui Du, M.S., Niels Weinhold, PhD, Gregory Song, Kristin Alyse Rand, PhD MPH, David Van Den Berg, PhD, Amie Hwang, PhD MPH, Xin Sheng, MS, Victor Hom, M.S., Sikander Ailawadhi, MD, Ajay K Nooka, MDMPH, Seema Singhal, MD, Edward S. Peters, DMD, SM, SM, ScD, Cathryn Bock, PhD, Ann Mohrbacher, MD, Alexander Stram, M.S., Sonja I Berndt, PhD, William J. Blot, PhD, Esther M. John, Leslie Bernstein, PhD, M.S., Antoinette Stroup, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Andrew Olshan, Wei Zheng, MD PhD, Sue Ann Ingles, PhD, Michael Press, PhDMD, John David Carpten, PhD, Stephen J Chanock, MD, Jayesh Mehta, MD, Graham A Colditz, MD DrPH, Jeffrey Wolf, Thomas G. Martin, III, MD, Mark A. Fiala, BS, Howard R. Terebelo, DO, Nalini Janakiraman, MD, Laurence Kolonel, MD, PhD, Kenneth C. Anderson, MD, Loic Le Marchand, MD, PhD, Daniel Auclair, Brian C.-H. Chiu, PhD, Daniel Stram, PhD, Ravi Vij, MBBS, Leon Bernal-Mizrachi, MD, Gareth Morgan, MD PhD, Jeffrey A. Zonder, Carol Ann Huff, MD, Sagar Lonial, Robert Z. Orlowski, MD, PhD, David Conti, PhD, Christopher A. Haiman, PhD, Elad Ziv, MD, John S Witte, PhD, Wendy Cozen, DO,MPH

Blood (2019) 134 (Supplement_1): 4379.

https://doi.org/10.1182/blood-2019-129298

Published: 2019

Journal Articles

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Scott R. Goldsmith, MD, Mark A. Fiala, BS, Mark A. Schroeder, MD, Tanya M. Wildes, MD, Armin Ghobadi, MD, Ravi Vij, MBBS, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 4351.

https://doi.org/10.1182/blood-2019-131135

Published: 2019

Journal Articles

Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair

Kidist Ashami, BA, Sena Kim, PhD, Ravi Vij, MBBS, Julie K. Ritchey, Srikanth Santhanam, PhD, Sora Lim, MS, Sarah Peterson, Matthew Ciorba, MD, John F. DiPersio, MD PhD, Jaebok Choi, PhD

Blood (2019) 134 (Supplement_1): 4420.

https://doi.org/10.1182/blood-2019-126167

Published: 2019

Journal Articles

Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)

Sarah A. Holstein, MD PhD, Sarah Cooley, MD, Parameswaran Hari, MBBS, MD, Sundar Jagannath, MD, Catherine R Balint, BSc, William Van Der Touw, Michele L. Donato, MD, Philip L. McCarthy, MD, Paul K. Wallace, MS, PhD, Xiaokui Zhang, PhD, Robert Hariri, MD PhD, Mohamad A. Hussein, MDMBBS, Ravi Vij, MBBS

Blood (2019) 134 (Supplement_1): 4451.

https://doi.org/10.1182/blood-2019-128467

Published: 2019

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, MD, Ajay K Nooka, MDMPH, Leonard Heffner, MD, Craig E. Cole, MD, J Christine Ye, MDMSc, Ravi Vij, MBBS, Craig C Hofmeister, MDMPH, John Rushton, PhD, Zhengjia Chen, PhD, Zhao Chang, PhD, Munevver Cinar, MD, Daniel Auclair, Sagar Lonial, Jonathan L. Kaufman, MD

Blood (2019) 134 (Supplement_1): 3188.

https://doi.org/10.1182/blood-2019-131223

Published: 2019

Journal Articles

Single-Cell Transcriptomic and Proteomic Diversity in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 5531.

https://doi.org/10.1182/blood-2019-131005

Published: 2019

Journal Articles

Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma

Justin King, Mark A. Fiala, BS, Scott R. Goldsmith, MD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Armin Ghobadi, MD, Ravi Vij, MBBS, Tanya M. Wildes, MD

Blood (2019) 134 (Supplement_1): 5701.

https://doi.org/10.1182/blood-2019-130689

Published: 2019

NARROW

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE ® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma

A Preliminary Assessment of Heterozygous CFHR3-CFHR1 Deletion As a Permissive Mutation in Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome

Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma

Inhibition of HIF-1a By PX-478 Normalizes Blood Vessels, Improves Drug Delivery and Suppresses Progression and Dissemination in Multiple Myeloma

Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Commpass Study

A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study

TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair

Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Single-Cell Transcriptomic and Proteomic Diversity in Multiple Myeloma

Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only